Sienna Cancer Diagnostics Appoints Helen Fisher to Board


Sienna is pleased to announce the appointment of Helen Fisher as an Independent Non-Executive Director and Chair of the Audit and Risk Committee effective 28 March 2018.

Sienna’s Chairman, Geoff Cumming said “We are very pleased to welcome Helen to Sienna’s Board. She brings great financial acumen, including accounting and taxation expertise, which, combined with her deep knowledge of the Life Sciences industry and her extensive network in the investment community, make Helen a valuable addition to our Board.”

Previously, a partner at Deloitte for 10 years, Ms Fisher has an exemplary track record, including leading Deloitte Australia’s Life Sciences Industry team and advising many Life Sciences and Biotechnology companies.

In July 2017, Ms Fisher established a new global Life Sciences fund, Bio Capital Impact Fund, investing in disruptive, high-growth Life Science and Biotechnology companies. She has also worked with the Australian Government and industry associations to achieve positive policy changes for the sector. Additionally, Ms Fisher has advised on the effective tax management of intellectual property, mergers and acquisition and product licensing, all areas of great relevance to Sienna.

On joining Sienna, Ms Fisher said: “I am delighted to join Sienna’s Board and look forward to contributing to the worldwide commercialisation of the Company’s technology and working alongside Sienna’s team in growing the Company.”



No Very

Captcha Image

Sign up for updates